Leucocyte zinc in non-Hodgkin's lymphoma and Hodgkin's disease.
Zinc status and the effect of zinc supplementation were assessed in groups of patients with non-Hodgkin's lymphoma and Hodgkin's disease; patients were either untreated or in remission. In the patients in remission, plasma zinc was normal; and whereas 30% of untreated patients had low plasma zinc, the group as a whole did not differ from normal. For mononuclear cell zinc, the range of values in the disease group was far wider than in controls, but there was no significant difference between the means of the groups. Granulocyte zinc was significantly lower in both the groups of patients in remission from non-Hodgkin's lymphoma and Hodgkin's disease compared with the control group. Significant increases were found in the plasma copper, ceruloplasmin, and the copper-to-zinc ratio in several of the patient groups. Plasma zinc increased by 23% with zinc supplementation (50 mg elemental Zn/day), but there was no effect on mononuclear cell or granulocyte zinc. Apart from granulocyte zinc, there is little evidence of zinc deficiency in non-Hodgkin's lymphoma or Hodgkin's disease. However, the presence of depleted granulocyte zinc levels could modify the immune function of this cell population.
Field
H P
HP
Department of Medicine, St. James's University Hospital, Leeds, UK.
Jones
R
R
Walker
B E
BE
Kelleher
J
J
Simmons
A V
AV
D000328:Adult; D000368:Aged; D005260:Female; D006098:Granulocytes / Q000032:analysis; D006689:Hodgkin Disease / Q000097:blood* / Q000276:immunology; D006801:Humans; D007962:Leukocytes / Q000032:analysis*; D007963:Leukocytes, Mononuclear / Q000032:analysis; D008228:Lymphoma, Non-Hodgkin / Q000097:blood* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D015032:Zinc / Q000097:blood* / Q000627:therapeutic use
D015032:Zinc